****

**China Health Group Inc.**

**中國醫療集團有限公司**

(Carrying on business in Hong Kong as “萬全醫療集團”)

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 08225)**

**Supplementary Announcement**

**CHANGE OF DIRECTORS**

**AND CHANGE IN COMPOSITION OF BOARD COMMITTEES**

Reference is made to the announcement of China Health Group Inc. (the "Company") dated February 5, 2024 (the "Announcement") in relation to the change of directors and change of composition of board committees. Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the Announcement.

Relevant experience regarding the competence of directors to hold office was required to be disclosed additionally, the Company would like to provide further clarification to the announcement in relation to "The curricula vitae of Mr. Wu and Dr. Wang are set out below: ......".

Mr. Wu Shuangsi ("Mr. Wu") graduated from Tsinghua University and the University of Hawaii, USA, and obtained an MBA degree (Finance) from the School of Business of the University of Hawaii. Both his undergraduate and master's degrees were systematically studied in the courses of financial analysis, financial management, financial auditing and finance, and he possesses the relevant professional knowledge in financial management. He has served in financial management and financial director positions in companies such as Tianjin Warm Current Enterprise Management Consulting Co. and China Sports Training (Beijing) Sports Development Company Limited. as well as in charge of financial matters in related fund companies, and has financial related experience and unique insights into the field of financial management.

 Dr. WANG Dajun Denis (“Dr. Wang“)worked on Wall Street as a vice president and senior analyst at Goldman Sachs Co. and Deutsche Bundesbank. Dr. Wang has more than 30 years of experience in cross-border and cross-industry strategic planning, business development as well as investment and financing operations, and he is a state-introduced by China with "highly specialized" Category A foreign expert, as well as a composite talent with expertise in finance, investment, biomedicine and other industries. He has rich experience in investment and financing and corporate strategy consulting in the biomedical field.

By Order of the Board

**China Health Group Inc.**

 **GUO Xia**

*Chairman*

Hong Kong, 15 February 2024